William Haynes, MD
Ophthalmology · Asheville, NCNPI 1528040128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 27.3% of the total.
Across 69 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Alcon$548
- Johnson & Johnson Surgical Vision, Inc.$403
- Bausch & Lomb Americas Inc.$149
- Stryker$144
- Aerie Pharmaceuticals, Inc.$142
- plus $392 from 10 others
Across 58 payments — averaging $4632.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$193K
- Padagis US LLC$68K
- Perrigo Company PLC$8K
What the payments were for
- Food & beverage$2,42799%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $667 |
| Alcon | 10 | $548 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $403 |
| Bausch & Lomb Americas Inc. | 7 | $149 |
| Stryker | 1 | $144 |
| Aerie Pharmaceuticals, Inc. | 2 | $142 |
| Tarsus Pharmaceuticals, Inc. | 5 | $111 |
| Sight Sciences, Inc. | 5 | $94 |
| Omeros Corporation | 3 | $54 |
| Glaukos Corporation | 2 | $34 |
| Dompe US, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Rxsight Inc | 1 | $19 |
| Novartis | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| NEW World Medical,inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$246
- Rocklatan$246
- Hydrus Microstent$147
- CITREFIX$144
- 7 X 23MM CITRELOCK IMPLANT$144
- XEN$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- SIMBRINZA$121
- OZURDEX$112
- DURYSTA$110
How this compares
$2,445 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 356 | $184,976 |
| RocklatanNetarsudil Mesylat/Latanoprost | 158 | $69,231 |
| RestasisCyclosporine | 58 | $59,439 |
| CombiganBrimonidine Tartrate/Timolol | 150 | $51,923 |
| Latanoprost | 3,111 | $38,091 |
| Travoprost | 171 | $28,333 |
| VyzultaLatanoprostene Bunod | 73 | $27,640 |
| Alphagan PBrimonidine Tartrate | 72 | $23,072 |
| RhopressaNetarsudil Mesylate | 50 | $22,041 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,217 | $21,889 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 125 | $19,442 |
| Brimonidine Tartrate | 953 | $16,177 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 67 | $16,130 |
| Timolol Maleate | 1,064 | $15,482 |
| Prednisolone Acetate | 308 | $12,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P, Restasis Multidose | $667 | $324,739647 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $142 | $91,273208 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $149 | $27,64073 claims |
| AlconSimbrinza | $548 | $16,13067 claims |
| NovartisTravatan Z | $15 | $9,13713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Asheville
- Christopher KomanskiAsheville$111K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.